Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial.

Robert D McBane IiCharles L LoprinziAneel AshraniCharles J LenzDamon HoughtonTyler ZemlaJennifer G Le-RademacherWaldemar E Wysokinski

Published in: European journal of haematology (2019)

We anticipate these trial results to provide evidence supporting low-dose apixaban as a safe agent for secondary prevention of cancer-associated VTE for patients who have already completed 6-12 months of anticoagulation.

Keyphrases

venous thromboembolism
direct oral anticoagulants
low dose
end stage renal disease
atrial fibrillation
study protocol
phase iii
newly diagnosed
ejection fraction
chronic kidney disease
clinical trial
prognostic factors
peritoneal dialysis
high dose
randomized controlled trial